Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Novartis’s US strategy for inclisiran; Roche under pressure over prices for Actemra in COVID; Lambda coronavirus variant poses new challenge for vaccines; GSK loses its oncology R&D head; and a look at expected Q3 approvals in the US.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 12 July 2021, including: Novartis AG’s US strategy for inclisiran; Roche Holding AG under pressure over prices for Actemra in COVID; Lambda coronavirus variant poses new challenge for vaccines; GlaxoSmithKline plc loses its oncology R&D head; and a look at expected Q3 approvals in the US.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Novartis Counts On Adherence, Access And Affordability To Ensure Inclisiran’s US Success" - Scrip, 6 Jul, 2021.)
(Also see "Shifting Goalposts For Vaccine Cos As Lambda Variant Rears Head" - Scrip, 7 Jul, 2021.)
(Also see "GSK's Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion" - Scrip, 7 Jul, 2021.)
(Also see "10 US Approval Decisions To Look Out For In Q3" - Scrip, 5 Jul, 2021.)